HMNY Short Interest Drops 41% as Penny Stock Fades
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
HMNY saw short interest plummet 41% over the past month. Shares short fell to 14,224 from 24,150 in late February.
The stock trades at $0.000001. Market cap data is unavailable. This is Helios and Matheson Analytics, the company behind the failed MoviePass subscription service.
Short interest remains minimal in absolute terms. Days to cover sits at 1.0. Cost to borrow was last recorded at 0.67% in early January, down 71% from prior readings.
Utilization stands at just 0.22%. This means almost no one is borrowing shares to short. The 52-week high for utilization was 0.25%.
Options data is stale, dating back to July 2018. Put/call ratio was 0.159 at that time. No recent options activity is available.
The company last reported earnings in February 2015. No analyst coverage exists. ORTEX's short score is 25.3 out of 100, indicating low short interest relative to peers.
HMNY filed for bankruptcy in 2019 after MoviePass collapsed. The stock has been effectively worthless for years. Trading volume is negligible.
The decline in short interest likely reflects covering by remaining shorts or simply expiring positions. With shares trading at a millionth of a dollar, there's no practical profit left to extract.
This is not a short squeeze candidate. It's a defunct company with zombie shares still technically trading.
This is not financial advice. ORTEX data may contain errors. Always verify information independently.
Stocks in this article
See the live data behind this article on ORTEX.
Open HMNY on ORTEX →How this article was generated
- Generated
- 22 Apr 2026, 22:30
- Data as of
- 22 Apr 2026, 22:29
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signals
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.